药物诱导的炎性肠病:胃肠病学家的实用指南
Maria José Temido1,2, Sailish Honap1,3,4, Anne Claire Bursztejn5
1INFINY Institute, Department of Gastroenterology, Nancy University Hospital, Nancy, France.
The American journal of gastroenterology
|October 9, 2024
概括
药物诱导是用于炎症性肠病 (IBD) 的Janus激酶抑制剂 (JAKi) 的常见副作用. 本综述为管理这种皮肤状况提供了指导,以改善患者的生活质量和IBD治疗的坚持.
科学领域:
- 皮肤病学 皮肤病学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 药物诱导是一种与各种药物相关的频繁不良事件,包括皮质类固醇和Janus激酶抑制剂 (JAKi).
- 类激酶抑制剂 (JAKi) 越来越多地用于炎症性肠病 (IBD) 和其他免疫媒介炎症疾病,导致人们对相关的形爆发更加关注.
- 是JAKi疗法中常见的治疗出现的不良事件,影响患者的生活质量和对IBD治疗的坚持.
研究的目的:
- 审查治疗IBD的患者中药物诱导的特征.
- 为胃肠科医生提供关于轻度至中度的实用管理指南.
- 确定何时需要专家皮肤科医生咨询,以获得最佳的患者护理.
主要方法:
- 对JAKi和的随机对照试验和真实研究的文献综述.
- 对药物诱导的临床表现和特征的分析.
- 为胃肠病学家开发一个管理算法.
主要成果:
- 在IBD治疗中,是与JAKi相关的普遍不良事件.
- 未经治疗的会对患者的自尊,生活质量和治疗坚持产生负面影响.
- 早期治疗策略可以防止治疗中止或剂量减少.
结论:
- 药物诱导的有效管理对于保持患者的坚持和优化IBD治疗结果至关重要.
- 胃肠道科医生可以通过实际指导来管理轻度至中度的形喷发.
- 及时转诊皮肤病学可以确保对药物诱导的复杂病例提供全面的护理.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Inflammatory Bowel Disease II: Crohn's Disease
191
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
191
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


